Astellas Pharma has initiated a global campaign to address the critical issue of delayed bladder cancer diagnoses. In collaboration with the World Bladder Cancer Patient Coalition (WBCPC) and behavioral scientists, the company aims to understand the barriers preventing individuals from seeking timely medical attention for bladder cancer symptoms.
Bladder cancer often goes undetected until advanced stages, significantly reducing survival rates. By exploring cultural, emotional, and societal factors influencing patient behavior, Astellas seeks to develop strategies that encourage earlier diagnosis and improve outcomes for those affected by this disease.
This initiative underscores Astellas’ commitment to patient-centric approaches and aligns with the broader efforts within the Leiden Bio Science Park to enhance healthcare through innovative research and collaboration.
Read more here
A month after being cleared to sell its animal-free meat fat in the US, Nourish Ingredients has set its sights on the global market with a new commercial hub in the Netherlands....
Dutch biotech Leyden Labs has raised a €30 million equity investment from the European Innovation Council (EIC) Fund and Invest-NL to accelerate the development of its PanFlu...
Leiden, 26 September 2025. For the first time, LUMC has used a surgical robot to remove a piece of liver from a living donor and successfully transplant it into a patient. A...